JP2012502955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502955A5 JP2012502955A5 JP2011527330A JP2011527330A JP2012502955A5 JP 2012502955 A5 JP2012502955 A5 JP 2012502955A5 JP 2011527330 A JP2011527330 A JP 2011527330A JP 2011527330 A JP2011527330 A JP 2011527330A JP 2012502955 A5 JP2012502955 A5 JP 2012502955A5
- Authority
- JP
- Japan
- Prior art keywords
- tyro3
- receptor
- cancer
- use according
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710002875 TYRO3 Proteins 0.000 claims 30
- 102100008605 TYRO3 Human genes 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 7
- 208000007097 Urinary Bladder Neoplasm Diseases 0.000 claims 5
- 238000010171 animal model Methods 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 230000000865 phosphorylative Effects 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 230000025458 RNA interference Effects 0.000 claims 2
- 108020004459 Small Interfering RNA Proteins 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 206010073370 Adenoid cystic carcinoma of salivary gland Diseases 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229960001904 EPIRUBICIN Drugs 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100008658 FN1 Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 101700018422 GAS6 Proteins 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 102000001253 Protein Kinases Human genes 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 102000029610 Protein S Human genes 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 1
- 229960001603 Tamoxifen Drugs 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 230000035578 autophosphorylation Effects 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002888 effect on disease Effects 0.000 claims 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 claims 1
- 229960004750 estramustine phosphate Drugs 0.000 claims 1
- 229960000752 etoposide phosphate Drugs 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229920002033 ribozyme Polymers 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Claims (15)
- ＴＹＲＯ３を過剰発現する癌の処置のための医薬を製造するためのＴＹＲＯ３チロシンキナーゼ阻害剤の使用。
- 阻害剤が、ＴＹＲＯ３の細胞外ドメインに対する抗体、ＴＹＲＯ３発現に特異的に干渉する核酸分子、キナーゼデッドドメインを提示するドミナントネガティブ受容体ＴＹＲＯ３、及びＴＹＲＯ３可溶性ベイトからなる群より選択される、請求項１記載の使用。
- ＴＹＲＯ３発現に特異的に干渉する核酸分子がＲＮＡｉ、アンチセンス核酸、又はリボザイムである、請求項２記載の使用。
- ＲＮＡｉがｓｉＲＮＡ、特に配列番号１の配列を含むｓｉＲＮＡである、請求項３記載の使用。
- ＴＹＲＯ３可溶性ベイトが、受容体の細胞外ドメインの少なくとも１つのＩｇ様又はフィブロネクチンＩＩＩドメインで構成される組換えＴＹＲＯ３受容体である、請求項２記載の使用。
- ＴＹＲＯ３可溶性ベイトが、Ｇａｓ６及び／又はプロテインＳに対する抗体である、請求項２記載の使用。
- ＴＹＲＯ３チロシンキナーゼの阻害剤が、別の活性成分、特に抗腫瘍薬物と組み合わせて使用される、請求項１〜６記載のいずれか一項記載の使用。
- 抗腫瘍薬物が、タモキシフェン、アロマターゼ阻害剤、トラスツズマブ、ＧｎＲＨアナログ、ゲムシタビン、ドセタキセル、パクリタキセル、マイトマイシン、シスプラチン、カルボプラチン、オキサリプラチン、ドキソルビシン、ダウノルビシン、ドセタキセル、シクロホスファミド、エピルビシン、フルオロウラシル、メトトレキセート、ミトキサントロン、ビンブラスチン、ビンクリスチン、ビノレルビン、ブレオマイシン、エストラムスチンリン酸、又はエトポシドリン酸からなる群から選択される、請求項７記載の使用。
- ＴＹＲＯ３を過剰発現する癌を処置するために適した分子をスクリーニング又は同定するための方法であって、方法が以下の工程：（ｉ）候補分子をＴＹＲＯ３受容体と接触させること、ならびに（ｉｉ）ＴＹＲＯ３受容体に結合し、及び／又はＴＹＲＯ３受容体のリガンドと及び／又はリガンドについて競合し、及び／又はＴＹＲＯ３基質のリン酸化もしくはＴＹＲＯ３自己リン酸化を減少させる能力を有する分子を選択すること、
を含む方法。 - ＴＹＲＯ３を過剰発現する癌を処置するために適した分子をスクリーニング又は同定するための方法であって、方法が以下の工程：（ｉ）候補分子を、ＴＹＲＯ３受容体を発現する細胞と接触させること、ならびに（ｉｉ）ＴＹＲＯ３受容体に結合し、及び／又はＴＹＲＯ３受容体のリガンドと及び／又はリガンドについて競合し、及び／又はＴＹＲＯ３遺伝子発現を減少させ、及び／又はＴＹＲＯ３基質のリン酸化もしくはＴＹＲＯ３自己リン酸化を減少させる能力を有する分子を選択すること、
を含む方法。 - ＴＹＲＯ３を過剰発現する癌の非ヒト動物モデルにおいて請求項９又は１０記載の方法により選択される分子を投与し、疾患進行に対する効果を分析する工程をさらに含む、請求項９又は１０記載の方法。
- ＴＹＲＯ３過剰発現が膀胱腫瘍であり、ＴＹＲＯ３を過剰発現する癌の非ヒト動物モデルが膀胱腫瘍の非ヒト動物モデルである、請求項１１記載の方法。
- ＴＹＲＯ３を過剰発現する癌が、膀胱腫瘍、びまん性大細胞型Ｂ細胞リンパ腫、唾液腺の腺様嚢胞癌、バーキットリンパ腫、多発性骨髄腫、膵管腺癌、ヘアリー細胞白血病、転移性前立腺癌、メラノーマ、及び結腸直腸癌からなる群より選択される、請求項１〜８のいずれか一項記載の使用、又は請求項９〜１２のいずれか一項記載の方法。
- ＴＹＲＯ３を過剰発現する癌が膀胱腫瘍である、請求項１３記載の使用又は方法。
- ＴＹＲＯ３チロシンキナーゼの阻害剤が、別の膀胱腫瘍処置と組み合わせて使用される、請求項１４記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305574.9 | 2008-09-19 | ||
| EP08305574A EP2165710A1 (en) | 2008-09-19 | 2008-09-19 | Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| PCT/EP2009/062091 WO2010031828A1 (en) | 2008-09-19 | 2009-09-18 | Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502955A JP2012502955A (ja) | 2012-02-02 |
| JP2012502955A5 true JP2012502955A5 (ja) | 2012-08-09 |
| JP5611953B2 JP5611953B2 (ja) | 2014-10-22 |
Family
ID=40203027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527330A Expired - Fee Related JP5611953B2 (ja) | 2008-09-19 | 2009-09-18 | 癌の処置における治療標的としてのチロシンキナーゼ受容体ｔｙｒｏ３ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9233144B2 (ja) |
| EP (2) | EP2165710A1 (ja) |
| JP (1) | JP5611953B2 (ja) |
| CA (1) | CA2736438C (ja) |
| ES (1) | ES2575429T3 (ja) |
| WO (1) | WO2010031828A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012099968A1 (en) * | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
| CN105899236B (zh) * | 2014-01-10 | 2019-07-26 | 斯索恩生物制药有限公司 | 表现出改进的体内抗肿瘤活性的倍癌霉素adc |
| BR112017022255A2 (pt) | 2015-04-17 | 2018-08-28 | Centre Nat Rech Scient | anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica |
| WO2019146805A1 (ja) * | 2018-01-29 | 2019-08-01 | 国立大学法人東京医科歯科大学 | 前頭側頭葉変性症治療剤、前頭側頭葉変性症治療剤のスクリーニング方法、及び前頭側頭葉変性症の治療方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| US20040053876A1 (en) | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| ES2550609T3 (es) | 2002-07-10 | 2015-11-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Interferencia de ARN mediante de moléculas de ARN de cadena sencilla |
| AU2003304180A1 (en) * | 2002-09-24 | 2005-01-04 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| US20050175616A1 (en) | 2003-05-30 | 2005-08-11 | Peter Kiener | PCDGF receptor antibodies and methods of use thereof |
| EP1720567A2 (en) | 2004-02-10 | 2006-11-15 | Innate Pharma | Composition and method for the treatment of carcinoma |
| JP2009502112A (ja) | 2005-07-28 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 腎細胞癌を診断および処置するための方法 |
| WO2007044894A2 (en) * | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| US20070275923A1 (en) | 2006-05-25 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY |
| PT2084162E (pt) | 2006-10-23 | 2012-10-09 | Sgx Pharmaceuticals Inc | Triazoles bicíclicos como moduladores de proteína quinase |
| JP2010511382A (ja) * | 2006-12-01 | 2010-04-15 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 癌関連タンパク質キナーゼ |
-
2008
- 2008-09-19 EP EP08305574A patent/EP2165710A1/en not_active Withdrawn
-
2009
- 2009-09-18 US US13/062,804 patent/US9233144B2/en not_active Expired - Fee Related
- 2009-09-18 ES ES09783150.7T patent/ES2575429T3/es active Active
- 2009-09-18 CA CA2736438A patent/CA2736438C/en not_active Expired - Fee Related
- 2009-09-18 WO PCT/EP2009/062091 patent/WO2010031828A1/en active Application Filing
- 2009-09-18 JP JP2011527330A patent/JP5611953B2/ja not_active Expired - Fee Related
- 2009-09-18 EP EP09783150.7A patent/EP2334303B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kok et al. | Cancer-derived exosomes: their role in cancer biology and biomarker development | |
| Rossow et al. | LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy | |
| Chen et al. | SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis | |
| Stratford et al. | Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells | |
| Liu et al. | Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone | |
| Liu et al. | Targeting YAP and Hippo signaling pathway in liver cancer | |
| Sun et al. | MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1 | |
| Kim et al. | Activation of KRAS promotes the mesenchymal features of basal-type breast cancer | |
| Soroceanu et al. | Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target | |
| Lin et al. | miR‐639 regulates transforming growth factor beta‐induced epithelial–mesenchymal transition in human tongue cancer cells by targeting FOXC 1 | |
| Yamato et al. | PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis | |
| Kato et al. | Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer | |
| Sun et al. | MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway | |
| Pal et al. | Triple-negative breast cancer: novel therapies and new directions | |
| Yuan et al. | Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients | |
| Hsu et al. | Lung tumor-associated dendritic cell-derived amphiregulin increased cancer progression | |
| Datar et al. | RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration | |
| Tang et al. | BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability | |
| Matsuoka et al. | The tumour stromal features are associated with resistance to 5‐FU‐based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma | |
| Liu et al. | The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma | |
| Bibby et al. | MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma | |
| Chang et al. | Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway | |
| Liu | The ROCK signaling and breast cancer metastasis | |
| Jang et al. | ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma | |
| de Hoon et al. | Taxane resistance in breast cancer: a closed HER2 circuit? |